Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Salewski

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Medical and Pediatric Oncology|January 1, 1994
Prospects for pirarubicinA A Miller, E Salewski
Cancer|August 15, 1990
A phase II study of pirarubicin in malignant pleural mesotheliomaE Kaukel, G Koschel, U Gatzemeyer, et al.
Intervirology|January 1, 1989
Genome structure of adenovirus 12 host range mutants adapted to growth in simian Vero cellsE Salewski, G Werner, B Opalka, et al.
Scandinavian Journal of Infectious Diseases|November 17, 1998
A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumoniaS R Norrby, W Petermann, P A Willcox, et al.
Pharmacoeconomics|March 8, 1997
Cost-minimisation analysis of sequential treatment with ofloxacin or ciprofloxacin in hospitalised patientsE Salewski, H P Bassaris, S Calangu, et al.
Onkologie|June 1, 1990
Pirarubicin in advanced non-small cell lung cancer. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer SocietyP Drings, I U Günther, U Gatzemeier, et al.
Infection|July 1, 1995
A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once dailyH Bassaris, E Akalin, S Calangu, et al.
Journal of Equine Veterinary Science|April 10, 2026
Successful Use of Vincristine in a Quarter Horse Gelding with Immune-Mediated ThrombocytopeniaK E Salewski, M A Talavera, G A Gonzalez, et al.
Onkologie|June 1, 1990
Phase II study of pirarubicin in metastatic breast cancerU R Kleeberg, L Reichel, H E Wander, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1989
Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumorsJ Verweij, M E van der Burg, W L van Putten, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Medical and Pediatric Oncology|January 1, 1994
Prospects for pirarubicinA A Miller, E Salewski
Cancer|August 15, 1990
A phase II study of pirarubicin in malignant pleural mesotheliomaE Kaukel, G Koschel, U Gatzemeyer, et al.
Intervirology|January 1, 1989
Genome structure of adenovirus 12 host range mutants adapted to growth in simian Vero cellsE Salewski, G Werner, B Opalka, et al.
Scandinavian Journal of Infectious Diseases|November 17, 1998
A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumoniaS R Norrby, W Petermann, P A Willcox, et al.
Pharmacoeconomics|March 8, 1997
Cost-minimisation analysis of sequential treatment with ofloxacin or ciprofloxacin in hospitalised patientsE Salewski, H P Bassaris, S Calangu, et al.
Onkologie|June 1, 1990
Pirarubicin in advanced non-small cell lung cancer. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer SocietyP Drings, I U Günther, U Gatzemeier, et al.
Infection|July 1, 1995
A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once dailyH Bassaris, E Akalin, S Calangu, et al.
Journal of Equine Veterinary Science|April 10, 2026
Successful Use of Vincristine in a Quarter Horse Gelding with Immune-Mediated ThrombocytopeniaK E Salewski, M A Talavera, G A Gonzalez, et al.
Onkologie|June 1, 1990
Phase II study of pirarubicin in metastatic breast cancerU R Kleeberg, L Reichel, H E Wander, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1989
Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumorsJ Verweij, M E van der Burg, W L van Putten, et al.
Pageof 2